What the trial was testing
The CAPTAIN enrolled 2,436 patients with asthma. The study was sponsored by GlaxoSmithKline and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
The triple-drug inhaler improved lung capacity by 110 mL more than the standard two-drug version.
The Lancet. Respiratory medicine · 2021 · NCT02924688
These findings — that triple-drug inhaler boosted breathing volume more than standard two-drug treatment — were published in the The Lancet. Respiratory medicine and represent the headline result of the study.
Researchers tracked outcomes across 2,436 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with asthma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This triple-combination inhaler is FDA-approved and available now for asthma patients who aren't well-controlled on a steroid plus long-acting bronchodilator. It improved breathing capacity significantly, though it didn't dramatically cut asthma attacks in this study. If your current asthma treatment isn't working well enough, ask your doctor whether adding a third medicine to your inhaler might help.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open asthma trials
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
This study is an observational multicenter cross-sectional study. Planned study population consists of 5 000 adult patients with uncontrolled SA receiving treatment according to standard of care (except biologics). Planned number of study site is 50 outpatient centers with experience of uncontrolled SA treatment in about 50 regions of Russia (in order to describe characteristics of patients with uncontrolled SA in different regions in the most comprehensive way). This non-interventional study does not imply any intervention into a routine clinical practice, and does not provide for any diagnostic and therapeutic procedures other than those used in routine practice.
A Non-interventional, Prospective Study With Benralizumab
This is a prospective, non-interventional, single-arm, multicenter study to investigate asthma control, and health-related quality of life (HRQL), lung function and asthma medication intake in severe eosinophilic asthma patients treated with benralizumab in a real-life setting in Germany.